Core Viewpoint - Matinas BioPharma Holdings, Inc. has appointed Keith Murphy and Edward Neugeboren as independent members of its Board of Directors, effective March 11, 2025, while Matthew Wikler and Natasha Giordano have stepped down from the Board [1][2] Group 1: Board Appointments - Keith Murphy and Edward Neugeboren bring extensive biotech industry experience to Matinas BioPharma's Board, which is expected to enhance the company's strategic direction and shareholder value [2] - Mr. Murphy will chair the Nominating and Governance Committee and join the Compensation Committee, while Mr. Neugeboren will chair the Compensation Committee and join the Audit Committee [2] Group 2: Profiles of New Board Members - Keith Murphy has a strong background in biotech, having co-founded Viscient Bio and previously led Organovo Holdings, with significant experience at Amgen, where he was involved in the development of denosumab, generating over $6 billion in annual sales [3][4] - Edward Neugeboren has over 33 years of experience in healthcare, including roles in corporate management and investment banking, and currently serves as Chief Strategy Officer at Cronus Pharma, leading various commercial operations [5][6][7] Group 3: Company Overview - Matinas BioPharma focuses on innovative therapies utilizing its lipid nanocrystal (LNC) platform technology [8] - The company's MAT2203 is a potential oral treatment for invasive fungal infections, designed to overcome limitations of existing therapies, and has shown promising results in Phase 2 studies [9]